NeurologyLive® Staff

Articles by NeurologyLive® Staff

Nusinersen Shows Long-Term SMA Success, Positive Data for an Investigational DMD Therapy, Zogenix to Resubmit Fenfluramine NDA

ByNeurologyLive® Staff

July 6th 2019

Neurology News Network for the week ending July 6, 2019.

Perampanel Monotherapy Promotes Seizure Freedom, Intranasal Midazolam Rapidly Effective, Safe Alternative in Status Epilepticus, Sleep Disorders and Epilepsy

ByNeurologyLive® Staff

June 29th 2019

Neurology News Network for the week ending June 29, 2019.

Solriamfetol Receives Schedule IV Designation for EDS in Narcolepsy, OSA, ABO-202 Gene Therapy Granted Fast Track Designation for Batten Disease, NfL Shows Multi-disease Usefulness

ByNeurologyLive® Staff

June 22nd 2019

Neurology News Network for the week ending June 22, 2019.

ILAE MRI Recommendations, CPAP in OSA and MCI, Lemborexant Positive for Insomnia

ByNeurologyLive® Staff

June 15th 2019

Neurology News Network for the week ending June 15, 2019.

FDA Approves Galcanezumab for Episodic Cluster Headache, FDA Clears ReStore Exo-Suit for Stroke Rehabilitation, Alzheimer Disease May Be Influenced by LDL-C Levels

ByNeurologyLive® Staff

June 8th 2019

Neurology News Network for the week ending June 8, 2019.

FDA Approves Zolgensma for Spinal Muscular Atrophy, Nerivio Migra Device Granted De Novo Clearance for Migraine, Cladribine Reduces MRI Lesions Across Subgroups in ORACLE-MS Study

ByNeurologyLive® Staff

June 1st 2019

Neurology News Network for the week ending June 1, 2019.

FDA OKs Atlas Stent System, Wearables in Epilepsy Monitoring, and ASA Policy Statement on Stroke Care Systems

ByNeurologyLive® Staff

May 25th 2019

Neurology News Network for the week ending May 25, 2019.

New Guideline for Tourette Syndrome, Tic Disorders, FDA Approves sBLA for IncobotulinumtoxinA for Blepharospasm, Gaboxadol Shows Clinical Benefit in Angelman Syndrome

ByNeurologyLive® Staff

May 18th 2019

Neurology News Network for the week ending May 18, 2019.

Inebilizumab for NMOSD, New Acute Migraine Clinical Trial End Points, Eptinezumab's Pending BLA for Migraine Prevention

ByNeurologyLive® Staff

April 27th 2019

Neurology News Network for the week ending April 27, 2019.

Exome Panel Promising for Diagnosing Epilepsy, Pamrevlumab for Duchenne Muscular Dystrophy Receives Orphan Drug Designation, Riluzole NDA Accepted for ALS

ByNeurologyLive® Staff

April 20th 2019

Neurology News Network for the week of April 20, 2019.

Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome

ByNeurologyLive® Staff

April 13th 2019

Neurology News Network for the week of April 13, 2019.

Clardibine Approved for Relapsing, Secondary Progressive MS, Cervella Cranial Electrotherapy Approved for Insomnia, and Management of Stroke With Tandem Occlusion

ByNeurologyLive® Staff

April 6th 2019

Neurology News Network for the week of April 6, 2019.

Siponimod Approved for SPMS, AVP-786 Phase 3 Results for Treatment of Agitation in Alzheimer-Related Dementia, and Mobile Technology for Care of Parkinson Disease

ByNeurologyLive® Staff

March 30th 2019

Neurology News Network for the week of March 30, 2019.

Quality of Life is Predictive of DBS Outcomes in Early Parkinson, Lack of Approved Therapies for MS Symptoms, and Ubrogepant for Acute Treatment of Migraine in Adults

ByNeurologyLive® Staff

March 23rd 2019

Neurology News Network for the week of March 22, 2019.

Ned Sharpless as Acting FDA Commissioner, Temelimab in MS Extension Trial, and Post-Stroke Blood Panel Predicting Dementia

ByNeurologyLive® Staff

March 16th 2019

Neurology News Network for the week of March 16, 2019.

Gottlieb Resignation, Priority Review Granted to Galcanezumab for Prevention of Episodic Cluster Headache, Neurologists Treating MS Deviate From DMT Use

ByNeurologyLive® Staff

March 9th 2019

Neurology News Network for the week of March 9, 2019.

NDA Accepted for SRP-4053 for DMD, MPRI 2.0 Differentiates Parkinson and Progressive Supranuclear Palsy, and Young Donor Plasma Infusion Warning

ByNeurologyLive® Staff

February 23rd 2019

Neurology News Network for the week of February 23, 2019.

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

ByNeurologyLive® Staff

February 16th 2019

Neurology News Network for the week of February 14, 2019.

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

ByNeurologyLive® Staff

February 2nd 2019

Neurology News Network for the week of February 2, 2019.

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

ByNeurologyLive® Staff

January 26th 2019

Neurology News Network for the week of January 26, 2019.

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

ByNeurologyLive® Staff

January 19th 2019

Neurology News Network for the week of January 19, 2019.

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

ByNeurologyLive® Staff

January 12th 2019

Neurology News Network for the week of January 12, 2019.

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

ByNeurologyLive® Staff

January 5th 2019

Neurology News Network for the week of January 5, 2019.

Oxtellar XR Approved as Monotherapy, Pregnancy Safety Data for Betaseron, and Biologic Brain Changes in Migraine

ByNeurologyLive® Staff

December 22nd 2018

Neurology News Network for the week of December 22, 2018.

Zilucoplan for Mysathenia Gravis, AXS-05 for Agitation in Alzheimer, and Chronic Migraine Management

ByNeurologyLive® Staff

December 15th 2018

Neurology News Network for the week of December 15, 2018.

Fingolimod Issued a Safety Warning, an NDA for BHV-0223 for ALS, and Lifestyle Modifications for Patients with Migraine

ByNeurologyLive® Staff

December 8th 2018

Neurology News Network for the week of December 1, 2018.

Galcanezumab for Cluster Headache, a Link Between Carotid Webs and Stroke, Managing Migraine Patient Relationships

ByNeurologyLive® Staff

November 24th 2018

Neurology News Network for the week of November 24, 2018.

An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use

ByNeurologyLive® Staff

November 17th 2018

Neurology News Network for the week of November 17, 2018.

Confounding Outcomes in Alzheimer, AFib and Dementia Risk, Cognitive Issues in Epilepsy, and MRI Imaging

ByNeurologyLive® Staff

November 10th 2018

Neurology News Network for the week of November 10, 2018.

Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine

ByNeurologyLive® Staff

November 3rd 2018

Neurology News Network for the week of November 3, 2018.

NeurologyLive® Staff

Articles by NeurologyLive® Staff

Nusinersen Shows Long-Term SMA Success, Positive Data for an Investigational DMD Therapy, Zogenix to Resubmit Fenfluramine NDA

Perampanel Monotherapy Promotes Seizure Freedom, Intranasal Midazolam Rapidly Effective, Safe Alternative in Status Epilepticus, Sleep Disorders and Epilepsy

Solriamfetol Receives Schedule IV Designation for EDS in Narcolepsy, OSA, ABO-202 Gene Therapy Granted Fast Track Designation for Batten Disease, NfL Shows Multi-disease Usefulness

ILAE MRI Recommendations, CPAP in OSA and MCI, Lemborexant Positive for Insomnia

FDA Approves Galcanezumab for Episodic Cluster Headache, FDA Clears ReStore Exo-Suit for Stroke Rehabilitation, Alzheimer Disease May Be Influenced by LDL-C Levels

FDA Approves Zolgensma for Spinal Muscular Atrophy, Nerivio Migra Device Granted De Novo Clearance for Migraine, Cladribine Reduces MRI Lesions Across Subgroups in ORACLE-MS Study

FDA OKs Atlas Stent System, Wearables in Epilepsy Monitoring, and ASA Policy Statement on Stroke Care Systems

New Guideline for Tourette Syndrome, Tic Disorders, FDA Approves sBLA for IncobotulinumtoxinA for Blepharospasm, Gaboxadol Shows Clinical Benefit in Angelman Syndrome

Inebilizumab for NMOSD, New Acute Migraine Clinical Trial End Points, Eptinezumab's Pending BLA for Migraine Prevention

Exome Panel Promising for Diagnosing Epilepsy, Pamrevlumab for Duchenne Muscular Dystrophy Receives Orphan Drug Designation, Riluzole NDA Accepted for ALS

Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome

Clardibine Approved for Relapsing, Secondary Progressive MS, Cervella Cranial Electrotherapy Approved for Insomnia, and Management of Stroke With Tandem Occlusion

Siponimod Approved for SPMS, AVP-786 Phase 3 Results for Treatment of Agitation in Alzheimer-Related Dementia, and Mobile Technology for Care of Parkinson Disease

Quality of Life is Predictive of DBS Outcomes in Early Parkinson, Lack of Approved Therapies for MS Symptoms, and Ubrogepant for Acute Treatment of Migraine in Adults

Ned Sharpless as Acting FDA Commissioner, Temelimab in MS Extension Trial, and Post-Stroke Blood Panel Predicting Dementia

Gottlieb Resignation, Priority Review Granted to Galcanezumab for Prevention of Episodic Cluster Headache, Neurologists Treating MS Deviate From DMT Use

NDA Accepted for SRP-4053 for DMD, MPRI 2.0 Differentiates Parkinson and Progressive Supranuclear Palsy, and Young Donor Plasma Infusion Warning

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

Oxtellar XR Approved as Monotherapy, Pregnancy Safety Data for Betaseron, and Biologic Brain Changes in Migraine

Zilucoplan for Mysathenia Gravis, AXS-05 for Agitation in Alzheimer, and Chronic Migraine Management

Fingolimod Issued a Safety Warning, an NDA for BHV-0223 for ALS, and Lifestyle Modifications for Patients with Migraine

Galcanezumab for Cluster Headache, a Link Between Carotid Webs and Stroke, Managing Migraine Patient Relationships

An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use

Confounding Outcomes in Alzheimer, AFib and Dementia Risk, Cognitive Issues in Epilepsy, and MRI Imaging

Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission

Understanding the Barriers of Health Insurance in Stroke Rehabilitation Care

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials